SCHEMBL12307789

SCHEMBL12307789

CN1CCc2cc(N3CCn4nc(NC(=O)C5CCCC5)cc43)ccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ GSK3B P49841 2/20 0.36
▸ GRM5 P41594 1/20 0.35
▸ ABL1 P00519 3/20 0.35
▸ CTSK P43235 1/20 0.35
▸ CTSC P53634 1/20 0.35
▸ HTR1A P08908 3/20 0.34
▸ HTR1F P30939 2/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ HTR1D P28221 1/20 0.34
▸ HTR1B P28222 1/20 0.34
▸ BUB1 O43683 1/20 0.34
▸ SLC6A4 P31645 1/20 0.33
▸ HRH1 P35367 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ PIK3C3 Q8NEB9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12307809 0.91 GSK3B (0.37) GSK3BCTSKCTSC
SCHEMBL12307833 0.88 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDHSD17B10GSK3B
SCHEMBL12307829 0.88 KCNH2 (0.37) ALDH1A1HPGDGSK3BGRM5HTR1A
SCHEMBL12307713 0.87 GRM5 (0.38) ALDH1A1HPGDGRM5ABL1KMT2A
SCHEMBL12307979 0.87 SLC5A1 (0.36) GRM5ABL1CTSKCTSCKMT2A
SCHEMBL12307980 0.87 SLC5A1 (0.36) GRM5ABL1CTSKCTSCKMT2A
SCHEMBL12307919 0.86 S1PR2 (0.36) ALDH1A1GRM5KMT2AKCNH2HRH3
SCHEMBL12307774 0.85 GRM5 (0.37) GRM5KMT2AKCNH2HRH3
SCHEMBL12307799 0.85 NPC1 (0.42) ABL1
SCHEMBL12308024 0.85 GRM5 (0.36) GRM5HTR1AKMT2AKCNH2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-22 — — US disclosed
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-22 — — US disclosed
EP-2327704-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY Shionogi&Co., Ltd. (JP) 2011-06-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY PIK3R5, PIK3R4, PIK3R1 ALDH1A1 3559/4885KDM4E 1658/4885HPGD 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback